Neuland Laboratories Ltd (NEULANDLAB) Q2FY26 Concall Summary - Sep-2025 Qtr
Performance Overview
- Neuland Laboratories Ltd achieved its best-ever quarterly revenue, reaching 516 crores, marking a significant 63.7% year-on-year increase from 315 crores in Q2 FY25.
- The robust growth was primarily propelled by the strong performance of Commercial CMS (Contract Manufacturing Services) projects, which contributed the majority share of the revenue.
- The company reported a healthy EBITDA of 156.9 crores, with an impressive EBITDA margin of 30.4%, benefiting from operating leverage due to the favorable business mix tilting towards CMS.
- Profit After Tax (PAT) stood at 96.5 crores, a substantial increase compared to 32 crores in Q2 FY25, reflecting improved operational efficiency and higher revenue.
- Management expressed optimism for FY26, anticipating it to be a year of strong growth, breaking away from the uneven performance observed in the previous four quarters, and building on the base of FY24.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.